




Fig. 1







Fig. 2



Microsoft Excel - demo - PATENT - 10/048,022 - Lerman - Sheet 3 of 64									
A1									
Cmpd									
Cmpd	Series	Test1	Test2	Test3	HTS SPA Dose-Resp % inh @ 3x10-6M	HTS SPA Dose-Resp % inh @ 1x10-6M	HTS SPA Dose-Resp % inh @ 3x10-7M	HTS SPA Dose-Resp % inh @ 1x10-7M	
Cmpd1	N		28	30	41	3	22	6	
Cmpd2	N		42	55	83	57	28	16	
Cmpd3	G		261	11	70	25	24	28	
Cmpd4	N			30	89	60	21	22	
Cmpd5	N		18	32	71	41	13	3	
Cmpd6	D	8.98	6.5	3.7	100	79	48	49	
Cmpd7	D	3.11	0.037	7.8	65	26	28	38	
Cmpd8	D		0.088	2.6	68	41	22	15	
Cmpd9	D	0.119			61	42	24	5	
Cmpd10	N	0.233			50	77	63	25	
Cmpd11	N	4.31			47	25	24	3	
Cmpd12	H	1.3	0.24		81	59	40	37	
Cmpd13	H	1.17	0.194	30	39	23	4	12	
Cmpd14	H	0.28	0.41		89	46	46	36	
Cmpd15	H	0.368	0.148		101	82	38	18	
Cmpd16	I		0.87	30	81	64	47	24	
Cmpd17	K		0.223	30	79	54	22	32	
Cmpd18	I	6.27			71	71	23	12	
Cmpd19	I	0.134			101	109	108	100	
Cmpd20	F		0.317		97	70	31	13	
Cmpd21	K		2.21		94	77	36	12	
Cmpd22	B		0.16		110	91	69	39	
Cmpd23	B		0.27		100	104	75	52	
Cmpd24	B	0.041	1.1		93	71	41	22	
Cmpd25	B	0.685			97	79	43	23	
Cmpd26	B	0.111			96	93	82	25	
Cmpd27	E		0.13		69	82	12	11	
Cmpd28	J		0.46		41	40	9	17	
Cmpd29	J	2.78	46						

302 304 306 308 310 312 314

Fig. 3A

Cirpd	Series	Test1	Test2	Test3	HTS SPA Dose-Resp % Inhib @ 3x10 ⁻⁶ M	HTS SPA Dose-Resp % Inhib @ 1x10 ⁻⁶ M	HTS SPA Dose-Resp % Inhib @ 3x10 ⁻⁷ M	HTS SPA Dose-Resp % Inhib @ 1x10 ⁻⁷ M
Comp24	J	227	24	30	106	62	18	3
Comp25	J	0.63			44	28		
Comp26	J		0.23		50	63	42	14
Comp27	N	123			56	20	38	20
Comp28	L	0.009	0.024		50	50	51	2
Comp29	F	0.05	0.41		87	73	29	15
Comp30	G	0.268	1.04		85	66	40	11
Comp31	O	0.018	0.35		58	46	28	13
Comp32	F	0.38	0.9		102	87	32	87
Comp33	H	4.45	0.13		38	25	18	12
Comp34	G	0.076	0.1		78	60	40	25
Comp35	F	0.5			111	110	104	82
Comp36	M	1.14			25	21	16	21
Comp37	F	0.025			109	104	97	80
Comp38	M	0.22			100	102	83	75
Comp39	M	0.035	0.043		71	43	31	15
Comp40	F	0.051			112	111	112	75
Comp41	G	0.079			78	70	44	27
Comp42	H	0.33	0.117	4.9	89	24	23	14
Comp43	A	0.005	0.18	1.6	108	102	53	27
Comp44	A	0.33			91	78	76	33
Comp45	G	9.12			61	64	60	26
Comp46	C	0.39			93	80	55	37
Comp47	A	0.018			101	72	42	29
Comp48	C	0.22			92	69	55	49

302

304

306

308

310

312

314

Fig. 3B



130-1 140 130-2 132 134 136 138 142

Click here to run these	Click here to run these	Click here to run these	Click here to run these	Click here to run these	Click here to run these
Sheet DEMO 3 column(s) 1-6 # of colors 6 break 1 break 2 break 3 break 4 break 5 color 1 color 2 color 3 color 4 color 5 color 6 Pre-scale air?	Sheet DEMO 3 column(s) 1-6 # of colors 6 break 1 break 2 break 3 break 4 break 5 color 1 color 2 color 3 color 4 color 5 color 6 Pre-scale air?	Sheet DEMO 3 column(s) 1-6 # of colors 6 break 1 break 2 break 3 break 4 break 5 color 1 color 2 color 3 color 4 color 5 color 6 Pre-scale air?	Sheet DEMO 3 column(s) 1-6 # of colors 6 break 1 break 2 break 3 break 4 break 5 color 1 color 2 color 3 color 4 color 5 color 6 Pre-scale air?	Sheet DEMO 3 column(s) 1-6 # of colors 6 break 1 break 2 break 3 break 4 break 5 color 1 color 2 color 3 color 4 color 5 color 6 Pre-scale air?	Sheet DEMO 3 column(s) 1-6 # of colors 6 break 1 break 2 break 3 break 4 break 5 color 1 color 2 color 3 color 4 color 5 color 6 Pre-scale air?

HELP

Fig. 4A

318

316

[illegible]

Fig. 4B

Fig. 5A



Sheet		DEMO 1
column(s)		C,D
# of colors		
break 1		0.1
break 2		1
break 3		5
break 4		
color 1		
color 2		
color 3		
color 4		
Re-scale all		no

Fig. 58



152

Sheet 1 of 3	
sheet	DEMO 3
column(s)	
# of colors	6
break 1	
break 2	
break 3	
break 4	
break 5	
color 1	
color 2	
color 3	
color 4	
color 5	
color 6	
Re-scale all?	

144

146


148

150

Fig. 6A



Fig. 6B






Fig. 6C



Fig. 7A: New Insects from 1005 Data Window									
Compd	Series	Test1	Test2	Test3	HTS SPA Dose-Resp % Inhd @ 3x10-5M	HTS SPA Dose-Resp % Inhd @ 1x10-5M	HTS SPA Dose-Resp % Inhd @ 3x10-7M	HTS SPA Dose-Resp % Inhd @ 1x10-7M	
Compd01	N		30	30	41	3	22	5	
Compd02	N		11	11	83	57	28	15	
Compd03	G		30	30	70	25	24	29	
Compd04	N		32	32	88	60	21	22	
Compd05	N		37	37	71	41	13	3	
Compd06	D		78	78	100	79	48	43	
Compd07	D		26	26	65	28	28	38	
Compd08	D				68	41	22	15	
Compd09	D	0.119			61	42	24	5	
Compd10	N	0.280			50	77	63	25	
Compd11	N	0.281			47	25	24	3	
Compd12	H	0.29			81	59	40	37	
Compd13	H	0.194			39	23	4	12	
Compd14	H	0.26			89	46	46	36	
Compd15	H	0.389			101	82	38	18	
Compd16	I	0.87			81	64	47	24	
Compd17	I	0.223			79	64	22	32	
Compd18	I	0.27			71	71	23	12	
Compd19	I	0.134			101	109	108	100	
Compd20	F	0.217			87	70	31	13	
Compd21	K	0.15			94	77	36	12	
Compd22	B				96	61	36	12	
Compd23	B				110	91	89	39	
Compd24	B	0.27			105	104	75	52	
Compd25	B				93	71	41	22	
Compd26	B	0.858			97	79	43	23	
Compd27	B	0.111			95	53	32	25	
Compd28	E	0.13			68	62	12	11	
Compd29	J	0.48			41	49	9	17	
Compd30	J				5	6	21	8	
Compd31	J				62	30	16	33	
Compd32	N				112	29	75	14	
Compd33	N				105	62	62	21	
Compd34	J								

Fig. 7A

Fig. 7B



Compd	Series	Test1	Test2	Test3	HTS SPA Dose-Resp % inh @ 3x10-6M	HTS SPA Dose-Resp % inh @ 1x10-6M	HTS SPA Dose-Resp % inh @ 3x10-7M	HTS SPA Dose-Resp % inh @ 1x10-7M
Compd1	N		35	20				
Compd2	N		41	11	83	3	22	9
Compd3	O		17	30	70	36	21	16
Compd4	N				88	30	21	22
Compd5	N		45	37	71	47	13	3
Compd6	D	3.35		13	10	79	14	18
Compd7	D	5.1		26	65	4	22	15
Compd8	D				89	4	23	5
Compd9	D	0.119			61	77	63	25
Compd10	N	0.233						
Compd11	N							
Compd12	H	0.09	0.24		81	31	23	3
Compd13	H	0.187	0.194	30				
Compd14	H	0.26	0.41					
Compd15	H	0.383	0.448					
Compd16	I			30				
Compd17	K		0.87		81			18
Compd18	I	5.72	0.223		79			21
Compd19	I	0.134			71			12
Compd20	F							
Compd21	K		0.17		97			12
Compd22	B		0.16			70		13
Compd23	B					77		12
Compd24	B		0.27			61		13
Compd25	B							
Compd26	B	0.885				71	28	22
Compd27	B	0.111				78	8	23
Compd28	E		0.12					25
Compd29	J		0.40		68	82	12	11
Compd30	J		15				9	17
Compd31	N						21	
Compd32	J						16	
Compd33	N						78	11

Fig. 8A

Fig. 8B

Fig. 9A



[illegible]


Fig. 9B

PATENT & TRADE MARK

USSN 10/048,022

LERMAN

Sheet 19 of 64





1100

Name	Color	Score	Name	Color	Score	Name	Color	Score
Sheet # DEMO1	Cluster Col A		Sheet # DEMO1	Cluster Col B		Sheet # DEMO3		
Cluster Col A			Cluster Col B					
Color	Score		Color	Score		Color	Score	
100	1		100	1				
Yellow			Yellow					
Columns	F1		Columns	F1		Columns		
Name: acids	Sheet # DEMO2	Cluster Col B	Name: amines	Sheet # DEMO3	Cluster Col C	Name:	Sheet # DEMO3	Cluster Col
Color	Score		Color	Score		Color	Score	
100	0		100	0				

HELP

If you specify
name then the
column in a row
here, the weight
will apply to EACH
of the columns.

© Zetec Inc. 1998

III: To quickly navigate among the
work-sheets in your workbook, especially if
you have a lot of them, RIGHT-click on any of
the tab-scrolling arrow buttons at the lower
left of the screen, to get a list of sheet names
to pick from.

Other shortcuts (see also the PANDORA
manual)
Ctrl-Shift-J goes to the Append Control

III: To capture the name of a sheet for an
entry into one of the control panels, double-
click the sheet's tab to get a "Rename
Sheet" dialog box. Then hit CTRL-C to
Edit: Copy the name to the clipboard, and
click Cancel on the Rename box. Go to the
cell where you want to paste the sheet
name, and either hit CTRL-V or do an
Edit: Paste.

Cluster Control All

Fig. 11A

314



Fig. 11B



Name		acids	
Sheet #		DEMO 2	
Cluster Col		B	
Color		Score	
red		0	
yellow		2	
Column(s)		Rel. Weight	
D		1	
		</	

Fig. 11C



Fig. 11D

Name:		Canid
Sheet #		DEMO 1
Cluster Col		A
Color		Score
Red		1
Yellow		1
Rel. Weight		1
C/D		1
E		1
Columns		F1



Microsoft Excel - demo "PANDORA" v23.1.xls [Read-Only]

B1		acid																	
name	acid	active group	activity @ 1 unit																
E1A	E1	A																	
E1B	E1	B	40																
E1C	E1	C	40																
E1D	E1	D																	
E2A	E2	A	7																
E2B	E2	B																	
E2C	E2	C	40																
E2D	E2	D																	
E3A	E3	A																	
E3B	E3	B																	
E3C	E3	C																	
E3D	E3	D																	
E4A	E4	A																	
E4B	E4	B																	
E4C	E4	C																	
E4D	E4	D																	
E5A	E5	A	3																
E5B	E5	B	5																
E5C	E5	C																	
E5D	E5	D	10																
E6A	E6	A																	

Fig. 12



CMFD ID	# of Implicates	S #	#PTS Test1	IC50 (nM) Test1	DATE Test1	#PTS Test2	IC50 (nM) Test2	DATE Test2	SELECT MTY
1-Dehtazodine				no effect, 10000	7/20/97	4	8384	4/10/97	
1-Dehtazodine				no effect, 10000	7/20/97	4	>10000 (blank)	4/10/97	
1-Dehtazodine				no effect, 10000	7/20/97	4	3153	3/6/98	0.00
1-Dehtazodine				no effect, 10000	7/20/97	4	3153	3/6/98	0.00
0277				1168.333333	3/6/97	3	(blank) 10000	3/6/98	0.00
0278				no effect	4/28/97	3	3575	3/6/98	38.21
0629				no effect	10/9/97				
0651				no effect	3/6/97	3	4100	3/9/97	15.59
0657				no effect	10/6/97				
0733				no effect	4/17/97	4	2885	3/6/98	679.87
0956				no effect	8/13/97	5	1283	8/18/97	32.08
1068				no effect	6/18/97	4	4000	6/23/97	8.39
10817-018-C				no effect	1/22/98				
1210				no effect	6/19/97	6	75000	6/24/97	2083.23
1329				no effect	8/13/97	5	23151	8/18/97	1158.05
1336				no effect	8/6/97	5	32303	8/7/97	310.41
1337				no effect	8/14/97	5	43105	8/20/97	
1338				no effect	8/6/97	5	>100000	8/7/97	
1339				no effect	8/14/97	5	85442	8/19/97	291.81
1341				no effect	8/14/97	5	>100000	8/19/97	
1342				no effect	8/6/97	5	34184	8/7/97	242.44
1343				no effect	7/29/97	5	62285	7/31/97	418.09
1344				no effect	7/25/97	5	5080	7/30/97	35.03
1352				no effect	7/19/97	4	63000	7/29/97	235.56
1353				no effect	7/19/97	4	no effect	7/29/97	
1420				no effect	8/13/97	5	4557	8/19/97	41.35
1431				no effect	7/29/97	5	15367	7/30/97	
1433				no effect	8/14/97	5	no effect	8/20/97	
1444				no effect	8/14/97	5	>100000	8/20/97	
1445				no effect	10/8/97				
1446				no effect	8/14/97	5	no effect	8/20/97	
1447				no effect	10/8/97				
1453				no effect	7/29/97	5	15484	7/30/97	453.21
1454				no effect	8/20/97				
1455				no effect	10/23/97				
1456				no effect	8/19/97	5	>100000	8/21/97	
1457				no effect	9/19/97				



CMFD ID	# of replicates	S #PTS Test1	IC50 (mM) Test1	DATE Test1	#PTS Test2	IC50 (mM) Test2	DATE Test2	SELECT MTY										
5533			134	6/20/97	4	11000	6/25/97	82.05										
6281				6/20/97	5	6000	6/25/97	171.43										
6476				9/17/97	5	2650	9/16/97	49.28										
6573			> 300	9/4/97	5	2486	9/11/97											
6741				9/17/97	5	1330	9/16/97	23.76										
6830				6/18/97	5	10000	6/23/97	1000.00										
7077			> 300	6/18/97	4	> 100000	6/23/97											
7338				10/6/97														
7368				6/12/97	4	419	4/10/97											
7781			> 10000	6/26/97	5	19000	7/3/97	231.71										
7946			63	6/12/97	5	200	12/7/97	3.17										
8374			185	7/27/97	5	2706	7/16/97	14.63										
8407				9/25/97														
8503			no effect	8/19/97	5	> 100000	8/21/97											
8516			165	8/13/97	5	1872	8/18/97	31.73										
8517				8/13/97	5	2836	8/18/97	72.72										
8671			> 300	7/23/97	5	35852	7/31/97											
8826				9/18/97	5	no effect	9/16/97											
8857			> 300	9/4/97	5	3233	9/9/97	16.18										
8858			no effect	9/4/97	5	9480	9/9/97											
8880			no effect	9/4/97	5	10630	9/9/97											
9116			108	7/28/97	5	16000	7/10/97	150.94										
9176				8/13/97	5	2013	8/18/97	46.76										
9177				8/13/97	5	1168	8/18/97	83.43										
9202			no effect	8/28/97	5	3143	9/9/97											
9386				1/22/98				0.00										
9557			> 300	10/3/97														
9751				11/14/97	5	1880	11/19/97	82.53										
9940				10/8/97														
DE-EAS			no effect	8/24/97	5	no effect (blank)	8/20/97											
DTG			> 10000	2/5/97	5	21360	2/28/97											
Haloperidol				6/12/97	5	800	2/6/97	1.11										
FP-EP				9/17/97	5	3570	9/16/97	123.10										
PPP			> 10000	3/7/97	5	75170	2/6/97											
propenone			8/24/97	8/24/97	5	no effect (blank)	8/20/97											
propenone			8/24/97	8/24/97	5	blank/no effect	8/20/97	0.00										

306

Fig. 13B



CWFO ID	# of replicates	S #	#PTS Test1	CSO (mV) Test1	DATE Test1	#PTS Test2	CSO (mV) Test2	DATE Test2	SELECT MTY
(+)penetration				no effect 10000	7/20/97	4	834	4/10/97	
(-)penetration				no effect 10000	7/20/97	4	> 10000(blank)	4/10/97	
(+)penetration				no effect 10000	7/20/97	4	313	35330	0.00
(-)penetration				no effect 10000	7/20/97	4	313	35330	0.00
0277				no effect	4/23/97	3	3576	35438	34.21
0278				no effect	10/9/97	3	4100	32937	15.59
0628				no effect	3/6/97	3	4100	32937	15.59
0651				no effect	10/9/97	3	4100	32937	15.59
0697				no effect	4/17/97	4	2885	35330	0.00
0733				no effect	4/17/97	4	2885	35330	0.00
0958				no effect	8/13/97	5	1283	8/18/97	32.08
1088				no effect	8/18/97	4	4000	8/23/97	8.59
10817-A18-C				no effect	1/22/98				
1210				no effect	7/18/97	4	6300	7/28/97	28.56
1329				no effect	7/18/97	4	6300	7/28/97	28.56
1336				no effect	8/12/97	5	4557	8/18/97	41.55
1337				no effect	7/20/97	5	15357	7/30/97	
1338				no effect	8/14/97	5	no effect	8/20/97	
1339				no effect	8/14/97	5	> 100000	8/20/97	
1341				no effect	10/9/97	5	no effect	8/20/97	
1342				no effect	8/14/97	5	no effect	8/20/97	
1343				no effect	10/9/97	5	no effect	8/20/97	
1344				no effect	8/14/97	5	no effect	8/20/97	
1362				no effect	10/9/97	5	no effect	8/20/97	
1363				no effect	8/14/97	5	no effect	8/20/97	
1364				no effect	10/9/97	5	no effect	8/20/97	
1420				no effect	8/14/97	5	no effect	8/20/97	
1431				no effect	10/9/97	5	no effect	8/20/97	
1439				no effect	8/14/97	5	no effect	8/20/97	
1444				no effect	10/9/97	5	no effect	8/20/97	
1445				no effect	8/14/97	5	no effect	8/20/97	
1446				no effect	10/9/97	5	no effect	8/20/97	
1447				no effect	8/14/97	5	no effect	8/20/97	
1453				no effect	10/9/97	5	no effect	8/20/97	
1454				no effect	8/14/97	5	no effect	8/20/97	
1455				no effect	10/9/97	5	no effect	8/20/97	
1456				no effect	8/14/97	5	no effect	8/20/97	
1457				no effect	10/9/97	5	no effect	8/20/97	

306

Fig. 13C

318

Fig. 13D

Fig. 13D

Panel 5/10

Original	Series	Test1	Test2	Test3	HTS SPA Dose-Resp X Inhib @ 3 μ M	HTS SPA Dose-Resp X Inhib @ 1 μ M	HTS SPA Dose-Resp X Inhib @ 0.3 μ M	HTS SPA Dose-Resp X Inhib @ 0.1 μ M
1								
2	Comp01	N						
3	Comp02	N						
4	Comp03	G						
5	Comp04	N						
6	Comp05	N						
7	Comp06	D						
8	Comp07	D						
9	Comp08	D						
10	Comp09	D	0.116					
11	Comp10	N	0.223					
12	Comp11	N						
13	Comp12	H						
14	Comp14	H	0.28					
15	Comp15	H	0.350					
16	Comp16	I						
17	Comp17	K						
18	Comp18	I	0.537					
19	Comp19	I	0.134					
20	Comp20	F						
21	Comp21	K						
22	Comp22	B						
23	Comp23	B						
24	Comp24	B	0.27					
25	Comp25	B						
26	Comp26	B	0.883					
27	Comp27	B	0.111					
28	Comp28	E	0.13					
29	Comp29							
30	Comp30							
31	Comp31							
32	Comp32							
33	Comp33							
34	Comp34							
35	Comp35							
36	Comp36							
37	Comp37							
38	Comp38							
39	Comp39							
40	Comp40							
41	Comp41							
42	Comp42							
43	Comp43							
44	Comp44							
45	Comp45							
46	Comp46							
47	Comp47							
48	Comp48							
49	Comp49							
50	Comp50							
51	Comp51							
52	Comp52							
53	Comp53							
54	Comp54							
55	Comp55							
56	Comp56							
57	Comp57							
58	Comp58							
59	Comp59							
60	Comp60							
61	Comp61							
62	Comp62							
63	Comp63							
64	Comp64							
65	Comp65							
66	Comp66							
67	Comp67							
68	Comp68							
69	Comp69							
70	Comp70							
71	Comp71							
72	Comp72							
73	Comp73							
74	Comp74							
75	Comp75							
76	Comp76							
77	Comp77							
78	Comp78							
79	Comp79							
80	Comp80							


Fig. 14A



USSN 10/048,022
LERMAN
Sheet 30 of 64

Cmpd	Series	Test1	Test2	Test3	HTS SPA Dose-Resp % inh @ 3x10-5M	HTS SPA Dose-Resp % inh @ 1x10-5M	HTS SPA Dose-Resp % inh @ 3x10-7M	HTS SPA Dose-Resp % inh @ 1x10-7M
Cmpd28	L				50			
Cmpd44	Q				70			
Cmpd45	M				71			
Cmpd43	A		0.18	1.5E-15			53	
Cmpd40	D			2.8	68			
Cmpd41	Q		0.35		68			
Cmpd42	H		0.117	4.5E-15	69			
Cmpd37	D							
Cmpd47	H		0.41					
Cmpd45	H	0.28	0.148					
Cmpd45	B							
Cmpd39	F	0.58	0.41					
Cmpd42	F	0.38	0.9					
Cmpd47	F							
Cmpd49	F							
Cmpd47	Q							
Cmpd49	A							
Cmpd49	D	0.119						
Cmpd48	N	0.23						
Cmpd42	H		0.24					
Cmpd49	I	0.134						
Cmpd20	F		0.317					
Cmpd22	B		0.15					
Cmpd24	B		0.27					
Cmpd25	B	0.883			71		58	
Cmpd27	B	0.111			70		22	
Cmpd28	E		0.13				22	
Cmpd29	J		0.46		62		11	
Cmpd35	J	0.63					3	
Cmpd36	J		0.22		63		18	
Cmpd38	Q	0.288						
Cmpd43	H		0.13					
Cmpd45	F	0.5						

Fig. 14B



cluster label	# of empts (unclustered)	score max 100 (scaled)	score
Cmpd38	1	67	
Cmpd44	1	67	
Cmpd46	1	67	
Cmpd48	1	67	
Cmpd53	1	67	
Cmpd58	1	60	
Cmpd61	1	50	
Cmpd62	1	50	
Cmpd67	1	33	
Cmpd14	1	33	
Cmpd15	1	33	
Cmpd25	1	33	
Cmpd39	1	33	
Cmpd42	1	33	
Cmpd47	1	33	
Cmpd50	1	33	
Cmpd51	1	33	
Cmpd57	1	33	
Cmpd59	1	17	
Cmpd10	1	17	
Cmpd12	1	17	
Cmpd19	1	17	
Cmpd20	1	17	
Cmpd22	1	17	
Cmpd24	1	17	
Cmpd26	1	17	
Cmpd27	1	17	
Cmpd28	1	17	
Cmpd29	1	17	
Cmpd33	1	17	
Cmpd35	1	17	
Cmpd36	1	17	
Cmpd38	1	17	
Cmpd40	1	17	
Cmpd43	1	17	
Cmpd48	1	17	
Cmpd49	1	17	
Cmpd54	1	17	
Cmpd56	1	17	

DEMO 1 SCORES by Cmpd

Fig. 14C




Fig. 14D

USSN 10/048,022
LERMAN
Sheet 33 of 64

cluster label	# of amps (uncloned)	score		max. 100 (uncloned)	max. 100 (4 equivs)
		max. 100	max. 100		
E1	4	82	82		
F2	4	82	82		
E7	4	83	83		
F1	4	76	76		
F6	4	67	67		
F3	4	58	58		
E2	4	50	50		
E3	4	33	33		
E4	4	26	26		
E5	4	17	17		
E6	4	17	17		
F4	4	17	17		
F5	4	8	8		
F7	4	8	8		

Fig. 15A





A	B	C	D	E
Cmpd	HTS SPA Dose-Resp % Inhib @ 3x10-6M	HTS SPA Dose-Resp % Inhib @ 1x10-6M	HTS SPA Dose-Resp % Inhib @ 3x10-7M	HTS SPA Dose-Resp % Inhib @ 1x10-7M
1				
2	Cmpd01		22	18
3	Cmpd02	41	3	5
4	Cmpd03		57	15
5	Cmpd04		25	29
6	Cmpd05		60	22
7	Cmpd06		41	3
8	Cmpd07			
9	Cmpd08	66	28	43
10	Cmpd09		41	38
11	Cmpd10	61	42	15
12	Cmpd11	50		5
13	Cmpd12	47	25	25
14	Cmpd13		1153	3
15	Cmpd14	39	23	40
16	Cmpd15		1146	4
17	Cmpd16			46
18	Cmpd17		64	38
19	Cmpd18		54	47
20	Cmpd19			22
21	Cmpd20			20

Figure 16A



Click here to download	
sheet	DEMO 1
column(s)	B:E
# of colors	1:33
break 1	33
break 2	67
break 3	
color 1	red
color 2	yellow
color 3	
Re-scale all?	

Figure 16B



A	B	C	D	E	F	G	H
Cmpd	HTS SPA Dose-Resp % Inhib @ 3x10-6M 3.00e-06	HTS SPA Dose-Resp % Inhib @ 1x10-6M 1.00e-06	HTS SPA Dose-Resp % Inhib @ 3x10-7M 3.00e-07	HTS SPA Dose-Resp % Inhib @ 1x10-7M 1.00e-07	D-R -iveness score (0 to 100) by Cmpd	D-R activity score (0 to 100) by Cmpd	D-R composite score (0 to 100) by Cmpd
Cmpd20	100	100	100	100	75	100	100
Cmpd07	100	59	48	43	83	77	79
Cmpd13	100	46	40	37	83	70	75
Cmpd15	100	46	46	36	83	70	75
Cmpd16	100	64	38	18	92	50	70
Cmpd17	100	64	47	24	92	43	67
Cmpd03	100	57	28	24	92	23	57
Cmpd05	100	60	21	15	92	23	57
Cmpd06	100	41	13	22	92	23	57
Cmpd09	100	41	22	15	92	23	57
Cmpd11	50	77	22	25	67	47	57
Cmpd18	100	54	22	32	92	23	57
Cmpd19	100	71	23	12	83	30	56
Cmpd10	61	42	24	5	83	20	51
Cmpd01	100	22	16	19	83	10	46
Cmpd04	100	25	24	29	83	10	46
Cmpd02	41	2	22	5	83	7	45
Cmpd08	66	28	28	38	58	33	45
Cmpd12	47	25	24	3	83	7	45
Cmpd14	38	23	4	12	83	7	45

Fig. 16c



A	B	C	D	E	F	G	H
cmpd	HTS SPA Dose-Resp % Inhib @ 3x10-6M 3.00e-06	HTS SPA Dose-Resp % Inhib @ 1x10-6M 1.00e-06	HTS SPA Dose-Resp % Inhib @ 3x10-7M 3.00e-07	HTS SPA Dose-Resp % Inhib @ 1x10-7M 1.00e-07	D-R -iveness score (0 to 100) by cmpd	D-R activity score (0 to 100) by cmpd	D-R composite score (0 to 100) by cmpd
22 marker_7.5					75	100	100
23 marker_7.0				50	83	87	86
24 marker_6.5			49	24	92	50	70
25 marker_6.0		50/117	23	9	92	23	57
26 marker_5.5	49	24	9	3	83	7	45
27 marker_5.0	23	9	9	1	75	0	38

Figure 16D



A	B	C	D	E	F	G	H	I	J
Cmpd	HTS SPA Dose-Resp % Inhib @ 3x10-6M 3.00e-06	HTS SPA Dose-Resp % Inhib @ 1x10-6M 1.00e-06	HTS SPA Dose-Resp % Inhib @ 3x10-7M 3.00e-07	HTS SPA Dose-Resp % Inhib @ 1x10-7M 1.00e-07	D-R Aveness score (0 to 100) by Cmpd	D-R activity score (0 to 100) by Cmpd	D-R composite score (0 to 100) by Cmpd	Interp log IC50 by Cmpd	est IC50 µM by Cmpd
1									
2	Cmpd20				75	100	100		<0.1
3	marker_7.5				75	100	100		
4	marker_7.0				83	87	88		
5	Cmpd07				83	77	79	6.78	0.17
6	Cmpd13				83	70	75	6.66	0.22
7	Cmpd15				83	70	75	6.66	0.22
8	Cmpd16				92	50	70	6.50	0.32
9	marker_6.5				92	50	70		
10	Cmpd17				92	43	67	6.38	0.41
11	Cmpd03				92	23	57	6.00	1
12	Cmpd05				92	23	57	6.00	1
13	Cmpd06				92	23	57	6.00	1
14	Cmpd09				92	23	57	6.00	1
15	Cmpd11				67	47	57	6.00	1
16	Cmpd18				92	23	57	6.00	1
17	marker_6.0				92	23	57		
18	Cmpd19				83	30	56	5.96	1.1
19	Cmpd10				83	20	51	5.75	1.8
20	Cmpd01				83	10	46	5.54	2.9
21	Cmpd04				83	10	46	5.54	2.9
22	Cmpd02				83	7	45		>3
23	Cmpd08				59	33	45		>3
24	Cmpd12				83	7	45		>3
25	Cmpd14				83	7	45		>3
26	marker_5.5				83	7	45		
27	marker_5.0				75	0	38		

Figure 16E



Fig. 16F

The complete data set for 3 points and 3 colors, in systematic order.

compound	percent inhibition		data group number		data group color	
	highest conc	lowest conc	highest conc	lowest conc	highest conc	lowest conc
compd 01	2	29	1	1		
compd 02	16	10	1	1		
compd 03	31	26	1	1		
compd 04	21	46	1	2		
compd 05	30	53	1	2		
compd 06	17	37	1	2		
compd 07	25	90	1	3		
compd 08	10	90	1	3		
compd 09	32	72	1	3		
compd 10	34	17	1	1		
compd 11	51	8	2	1		
compd 12	56	3	2	1		
compd 13	33	39	2	2		
compd 14	53	52	2	2		
compd 15	51	62	2	2		
compd 16	65	82	2	3		
compd 17	43	71	2	3		
compd 18	65	99	2	3		
compd 19	87	11	3	1		
compd 20	87	5	3	1		
compd 21	77	8	3	1		
compd 22	78	38	3	2		
compd 23	85	40	3	2		
compd 24	83	57	3	3		
compd 25	73	88	3	3		
compd 26	69	85	3	3		
compd 27	79	68	3	3		




Fig. 166

The complete data set for 3 points and 3 colors, sorted by decreasing dose-responsiveness

compound	highest conc	lowest conc	step scoring	unscaled score points	scaled responsiveness 0-100
compd 22			+1+1	2	100
compd 10			+1+0	1	88
compd 13			0+1	1	88
compd 19			+1+0	1	88
compd 23			+1+0	1	88
compd 25			0+1	1	88
compd 26			0+1	1	88
compd 01			0+0	0	75
compd 14			0+0	0	75
compd 27			0+0	0	75
compd 04			-3+1	-2	50
compd 07			-3+1	-2	50
compd 08			-3+1	-2	50
compd 11			+1-3	-2	50
compd 12			+1-3	-2	50
compd 18			-3+1	-2	50
compd 17			+1-3	-2	50
compd 20			+1-3	-2	50
compd 21			+1-3	-2	50
compd 24			0-3	-3	38
compd 02			0-3	-3	38
compd 03			-3+0	-3	38
compd 05			-3+0	-3	38
compd 09			0-3	-3	38
compd 15			-3+0	-3	38
compd 16			-3+0	-3	38
compd 06			-3+0	-3	38




Fig. 16H

The complete set of data for 3 points and 3 colors, sorted by decreasing overall activity.

compound	data group number			data group color			activity scoring	unscaled activity points	scaled activity 0-100
	highest conc	→	lowest conc	highest conc	→	lowest conc			
compd 27	3	3	3				1(3)+2(3)+3(3)	18	100
compd 18	2	3	3				1(2)+2(3)+3(3)	17	92
compd 24	3	2	2				1(3)+2(2)+3(3)	16	83
compd 09	1	3	3				1(1)+2(3)+3(3)	16	83
compd 26	3	3	2				1(3)+2(3)+3(2)	15	75
compd 16	2	2	3				1(2)+2(2)+3(3)	15	75
compd 17	2	3	2				1(2)+2(3)+3(2)	14	67
compd 21	3	1	3				1(3)+2(1)+3(3)	14	67
compd 06	1	2	3				1(1)+2(2)+3(3)	14	67
compd 23	3	3	2				1(3)+2(2)+3(2)	13	58
compd 08	1	3	3				1(1)+2(3)+3(2)	13	58
compd 12	2	1	3				1(2)+2(1)+3(3)	13	58
compd 25	3	2	2				1(3)+2(2)+3(1)	12	50
compd 14	2	3	3				1(2)+2(3)+3(1)	12	50
compd 03	1	1	3				1(1)+2(1)+3(3)	12	50
compd 16	2	3	1				1(2)+2(3)+3(1)	11	42
compd 20	3	3	1				1(3)+2(3)+3(1)	11	42
compd 05	1	2	2				1(1)+2(2)+3(2)	11	42
compd 22	3	3	1				1(3)+2(3)+3(1)	10	33
compd 11	2	1	2				1(2)+2(1)+3(2)	10	33
compd 13	2	2	1				1(1)+2(2)+3(1)	9	25
compd 02	1	1	2				1(3)+2(1)+3(1)	8	17
compd 19	3	1	1				1(1)+2(2)+3(1)	8	17
compd 04	2	2	1				1(2)+2(1)+3(1)	7	8
compd 10	1	1	1				1(1)+2(1)+3(1)	6	0

Fig. 16I



DATE CANCELLED
OCT 06 2003
OIP E J 008
OCT 03 2003
PATENT & TRADEMARK OFFICE

Fig. 16J


The complete set of data for 3 points and 3 colors, sorted by decreasing composite score.

compound	highest conc	lowest conc	scaled response-ness, 0-100	scaled activity 0-100	composite 0-100
compd 27			76	100	100
compd 18			38	92	82
compd 26			88	75	80
compd 24			50	83	72
compd 23			88	58	72
compd 09			38	83	68
compd 25			88	50	68
compd 22			100	33	68
compd 14			75	50	62
compd 15			38	75	61
compd 17			50	67	60
compd 21			50	67	60
compd 13			88	25	56
compd 08			50	58	54
compd 12			50	58	54
compd 19			88	17	52
compd 10			88	8	48
compd 16			50	42	46
compd 20			50	42	46
compd 03			38	50	44
compd 07			50	33	41
compd 11			50	33	41
compd 05			38	42	40
compd 06			0	67	38
compd 01			75	0	33
compd 04			50	17	33
compd 02			38	25	31





USSN 10/048,022
LERMAN
Sheet 45 of 64



Quality of Ranking when Noise = 10 Inhibition Percentage Points

Fig. 16K

Fig. 16L

Quality of Ranking when Noise = 30 Inhibition Percentage Points






Fig. 16M

Quantitative Estimation of Potencies by Calibration Marker Compounds

compound	% inh @ 3.00e-06	% inh @ 1.00e-08	% inh @ 3.00e-07	% inh @ 1.00e-07	D.R. composite score	interp -log IC50 /M	est IC50 /M
M33875	100	102	83	75	79		<0.1
marker 7.5	99	97	90	78	79	7.00	0.10
M221211	110	91	69	39	78	7.00	0.10
M371585	108	102	63	27	76	7.00	0.10
marker 7.0	97	91	75	30	76		
M345077	102	87	92	87	75	6.97	0.11
M371796	91	78	76	33	73	6.90	0.13
M143629	100	79	48	43	69	6.77	0.17
M371890	101	72	42	29	69	6.77	0.17
M371891	92	69	55	49	69	6.77	0.17
M309032	105	62	62		67	6.70	0.20
M198289	101	82	38		66	6.67	0.22
M224602	97	79	43		66	6.67	0.22
M318671	93	63	42		66	6.67	0.22
M273373	95	93	52		65	6.63	0.23
M371336	78	70	44	27	62	6.53	0.29
M371825	61	64	60	26	62	6.53	0.29
M181250	99	46	46	35	61	6.50	0.32
M338331	87	73	29		61	6.50	0.32
marker 6.5	90	76	49	24	61		
M143630	65	28	28	39	60	6.44	0.36



MAIL

USSN 10/048,022
LERMAN
Sheet 48 of 64






Fig. 16N

Quality of Estimation when Noise = 10 Inhibition Percentage Points

MAIL

Fig. 16P








Fig. 16Q

Comparison of Curve Fitting to Marker Calibration
for T-cell Proliferation Data






Compd	Series	Test1	Test2	Test3	HTS SPA			
					Dose-Resp % Inhib @ 3x10-6M	Dose-Resp % Inhib @ 1x10-6M	Dose-Resp % Inhib @ 3x10-7M	Dose-Resp % Inhib @ 1x10-7M
1	Compd01	N	29	30	41	3	22	5
2	Compd02	N	42	55	83	57	28	15
3	Compd03	G	261	11	70	25	24	29
4	Compd04	N		30	89	60	21	22
5	Compd05	N	1.8	9.2	71	41	13	3
6	Compd06	D	8.86	6.5	100	79	48	43
7	Compd07	D	3.11	0.037	65	28	28	38
8	Compd08	D	0.089	N.A.	68	41	22	15
9	Compd09	D	0.119		61	42	24	5
10	Compd10	N	0.233		50	77	63	25
11	Compd11	N	4.31		47	25	24	3
12	Compd12	H	1.3	0.24	81	59	40	37
13	Compd13	H	1.17	0.194	39	23	4	12
14	Compd14	H	0.26	0.41	99	46	46	36
15	Compd15	H	0.369	0.148	101	82	38	18
16	Compd16	K	0.87	30	79	54	22	32
17	Compd17	K	0.223	N.A.	71	71	23	12
18	Compd18		5.27		101	109	108	100
19	Compd19		0.134		87	70	31	13
20	Compd20		0.317		94	77	36	12
21	Compd21	K	2.21		96	61	36	12
22	Compd22	B	0.15		110	91	69	39
23	Compd23	B						
24	Compd24	B	3.487	0.27				

Figure 17A




THIS COLORING INDICATES A DATA COLUMN WITH MIXED DATA TYPES												
orig col	heading	# numeric	# text	# date	# blank	# total (longest col)	last occupied row num.	minimum (4 sig fig)	maximum (4 sig fig)	mean (4 sig fig)	standard dev (4 sig fig)	unique text strings and counts (24 different)
A	Compd		24			24	25					B (3) D (4) G (1) H (4) K (2) N (6)
B	Series		20		4	24	25					
C	Test1	12			12	24	25	0.119	8.86	2.385	2.726	
D	Test2	17			7	24	25	0.037	42	5.122	11.77	
E	Test3	10	2		12	24	25	0.4	30	15.76	12.59	NA (2)
F	HTS SPA Dose-Resp % Inhib @ 3x10-6M	23			1	24	25	39	110	77.57	20.43	
G	HTS SPA Dose-Resp % Inhib @ 1x10-6M	23			1	24	25	3	109	55.87	25.24	
H	HTS SPA Dose-Resp % Inhib @ 3x10-7M	23			1	24	25	4	108	35.52	21.85	
I	HTS SPA Dose-Resp % Inhib @ 1x10-7M	23			1	24	25	3	100	23.91	20.74	

Figure 17B




A	B	C	D	E	F	G
project name	most important factor scored by Mngt A	most important factor scored by Mngt B	most important factor scored by Mngt C	less important factor scored by Mngt A	less important factor scored by Mngt B	less important factor scored by Mngt C
1						
2 Proj 01	2		2	1	2	2
3 Proj 02	1	1	1	2	1	2
4 Proj 03	1	1		1	2	
5 Proj 04				1	2	1
6 Proj 05					1	2
7 Proj 06	2		1		2	1
8 Proj 07		1	1			1
9 Proj 08		1	2		1	
10 Proj 09			1		2	1
11 Proj 10	2	1		1		1
12 Proj 11	1	1	1	2	1	
13 Proj 12			1	1		2
14 Proj 13		1				2
15 Proj 14		2	2			
16 Proj 15	2		2	2	2	2
17 Proj 16	1	2	2	1	2	
18 Proj 17	2	1		2	2	2
19 Proj 18				1		
20 Proj 19	2	2	2		1	1
21 Proj 20		2		1		2

Figure 18A



Click here to run a test	
sheet	Portfolio
column(s)	B:G
# of colors	3
break 1	1
break 2	2
break 3	3
color 1	red
color 2	yellow
color 3	
Re-scale all?	

Figure 188



Name:		Factors
College Cluster Study		
Sheet #	Portfolio	
Cluster Col	A	
Serial Cluster Study		
Color	Score	
red	1	
yellow	2	
Score and Sort Clusters		
Columns	Rel. Weight	
B:D	3	
E:G	1	

Figure 18C



A	B	C	D	E	F	G	H
project name	most important factor scored by Mngr A	most important factor scored by Mngr B	most important factor scored by Mngr C	less important factor scored by Mngr A	less important factor scored by Mngr B	less important factor scored by Mngr C	score (0-100)
1							
2 Proj 18							94
3 Proj 05							92
4 Proj 04							86
5 Proj 14							83
6 Proj 20		2	2				83
7 Proj 13		2					81
8 Proj 09							75
9 Proj 12							75
10 Proj 15	2						75
11 Proj 01	2						72
12 Proj 08							69
13 Proj 06	2						67
14 Proj 17	2						67
15 Proj 19	2						64
16 Proj 07							61
17 Proj 03							58
18 Proj 10	2						58
19 Proj 16		2					58
20 Proj 02							39
21 Proj 11							36

Figure 18D

0
OCT 06 2003
PATENT & TRADEMARK OFFICE
CANCELLED

OCT 03 2003
PATENT & TRADEMARK OFFICE

USSN 10/048,022
LERMAN
Sheet 57 of 64

Fig. 19
Drug Candidate Compounds;
Scored, Sorted, and Vertically Compressed

Compd	Cluster	CD45 HTS	IRP HTS	APOP HTS	ACC	DON	dLogP	NMW	HTS Selectivity Ratio	Ratio A/Num	Pcrit Crt
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											
[REDACTED]											

OCT 06 2023

OCT 03 2023



Fig. 20 Target Protein Candidates

Profile:
reading, stim, aromatic
Validated
Repeat ddPCR
Molecule code
ID / Hom
Elec Nordism
Haem %
Relevant biology
Validatable target
Druggable target
Pathway

MAIL D

Fig. 21

project name	most important factor scored by manager 1	most important factor scored by manager 2	most important factor scored by manager 3	less important factor scored by manager 1	less important factor scored by manager 2	less important factor scored by manager 3
Proj 18						
Proj 05						
Proj 04						
Proj 14						
Proj 20						
Proj 13						
Proj 09						
Proj 12						
Proj 15						
Proj 01						
Proj 08						
Proj 06						
Proj 17						
Proj 19						
Proj 07						
Proj 03						
Proj 10						
Proj 16						
Proj 02						
Proj 11						






Fig. 22

Company	Disease 1	Disease 2	Disease 3	Disease 4	Disease 5	Disease 6	Disease 7	Disease 8	Disease 9	Disease 10	Disease 11	Disease 12
Company 1	Phase I				L/I/O			L/I/O	Phase I		Phase II	Phase I
Company 2	Phase I	LI	Phase II			L/I/O	L/I/O	L/I/O	L/I/O	L/I/O		
Company 3	L/I/O				L/I/O	Phase II	L/I/O	Phase II				
Company 4					L/I/O	Phase II	L/I/O	Phase II				
Company 5	L/I/O			L/I/O	L/I/O	Phase II						TS/LI
Company 6												
Company 7	L/I/O							Phase I		L/I/O	Phase I	LI
Company 8		Phase II			L/I/O			L/I/O	L/I/O			
Company 9	L/I/O					Phase I	L/I/O	L/I/O	L/I/O		L/I/O	L/I/O
Company 10				L/I/O	Phase III					Phase II		
Company 11				L/I/O	L/I/O							
Company 12			Phase II		L/I/O							L/I/O
Company 13	LI				Phase III		Phase III					LI
Company 14	L/I/O		L/I/O		L/I/O		L/I/O	L/I/O			L/I/O	
Company 15	LI		LI	LI	LI		Phase II			LI		
Company 16	LI											
Company 17	Phase II				L/I/O	L/I/O						
Company 18								Phase I				
Company 19	LI		LI				LI					
Company 20				L/I/O								
Company 21	L/I/O				Phase III							
Company 22	TS		TS			TS				TS		
Company 23	LI				L/I/O							
Company 24	LI											
Company 25	L/I/O											



OCT 03 2003
PATENT & TRADEMARK OFFICE

USSN 10/048,022
LERMAN
Sheet 61 of 64



OCT 03 2003

PATENT & TRADEMARK OFFICE

USSN 10/048,022

LERMAN

Sheet 62 of 64




Fig. 24

